These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31003059)

  • 21. Corrigendum to "A fluorine scan on the Zn
    Zhang B; Liu J; Gao D; Yu X; Wang J; Lei X
    Eur J Med Chem; 2020 Jul; 198():112340. PubMed ID: 32371332
    [No Abstract]   [Full Text] [Related]  

  • 22. Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].
    Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
    Eur J Med Chem; 2023 Apr; 252():115295. PubMed ID: 36989810
    [No Abstract]   [Full Text] [Related]  

  • 23. Corrigendum to "Synthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors" [Eur. J. Med. Chem. 181 (2019) 111562].
    Gaines T; Garcia F; Virani S; Liang Z; Yoon Y; Oum YH; Shim H; Mooring SR
    Eur J Med Chem; 2023 Dec; 261():115753. PubMed ID: 37634992
    [No Abstract]   [Full Text] [Related]  

  • 24. Corrigendum to 'Design, synthesis and in vitro study of densely functionalized oxindoles as potent α-glucosidase inhibitors' [Bioorg. Med. Chem. 26(18) (2018) 4996-5005].
    Luthra T; Naga Lalitha K; Agarwal R; Uma A; Sen S
    Bioorg Med Chem; 2018 Dec; 26(23-24):6153. PubMed ID: 30470596
    [No Abstract]   [Full Text] [Related]  

  • 25. Corrigendum to "Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors" [Eur. J. Med. Chem. 197 (2020) 112308].
    Shuai W; Li X; Li W; Xu F; Lu L; Yao H; Yang L; Zhu H; Xu S; Zhu Z; Xu J
    Eur J Med Chem; 2020 Aug; 200():112464. PubMed ID: 32512484
    [No Abstract]   [Full Text] [Related]  

  • 26. Corrigendum to: Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib [Eur. J. Med. Chem. 172 (2019) 143-153].
    Poratti M; Marzaro G
    Eur J Med Chem; 2020 Jun; 195():112272. PubMed ID: 32251743
    [No Abstract]   [Full Text] [Related]  

  • 27. Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).
    Gangjee A; Jain HD; Phan J; Lin X; Song X; McGuire JJ; Kisliuk RL
    J Med Chem; 2006 Feb; 49(3):1055-65. PubMed ID: 16451071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331].
    Mendes VIS; Bartholomeusz GA; Ayres M; Gandhi V; Salvador JAR
    Eur J Med Chem; 2016 Nov; 124():1004-1005. PubMed ID: 27783971
    [No Abstract]   [Full Text] [Related]  

  • 29. Synthesis and activity of novel 5-substituted pyrrolo[2,3-d]pyrimidine analogues as pp60(c-Src) tyrosine kinase inhibitors.
    Olgen S; Isgör YG; Coban T
    Arch Pharm (Weinheim); 2008 Feb; 341(2):113-20. PubMed ID: 18214841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corrigendum to "Optimization of physicochemical properties for 4-Anilinoquinazoline inhibitors of trypanosome proliferation" [Eur. J. Med. Chem. 141 (2017) 446-459].
    Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
    Eur J Med Chem; 2018 May; 152():515. PubMed ID: 29754075
    [No Abstract]   [Full Text] [Related]  

  • 31. Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors.
    Schlütke L; Immer M; Preu L; Totzke F; Schächtele C; Kubbutat MHG; Kunick C
    Eur J Pharm Biopharm; 2018 May; 126():89-94. PubMed ID: 28315448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corrigendum to "Design and synthesis of novel artemisinin hybrids with potent activities against human colorectal cancer cells in vitro and in vivo" [Eur. J. Med. Chem. 182 (2019) 111665].
    Wang LL; Kong L; Liu H; Zhang Y; Zhang L; Liu X; Yuan F; Li Y; Zuo Z
    Eur J Med Chem; 2020 May; 194():112256. PubMed ID: 32220686
    [No Abstract]   [Full Text] [Related]  

  • 33. Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.
    Kim J; Kwon J; Lee D; Jo S; Park DS; Choi J; Park E; Hwang JY; Ko Y; Choi I; Ju MK; Ahn J; Kim J; Han SJ; Kim TH; Cechetto J; Nam J; Ahn S; Sommer P; Liuzzi M; Lee J
    Bioorg Med Chem Lett; 2014 Dec; 24(23):5473-7. PubMed ID: 25455487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corrigendum to "Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease" [Eur. J. Med. Chem. 163 (2019), 307-319. DOI: 10.1016/j.ejmech.2018.11.040].
    Tang YW; Shi CJ; Yang HL; Cai P; Liu QH; Yang XL; Kong LY; Wang XB
    Eur J Med Chem; 2024 Sep; 275():116591. PubMed ID: 38890013
    [No Abstract]   [Full Text] [Related]  

  • 35. Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors.
    Nagashima S; Hondo T; Nagata H; Ogiyama T; Maeda J; Hoshii H; Kontani T; Kuromitsu S; Ohga K; Orita M; Ohno K; Moritomo A; Shiozuka K; Furutani M; Takeuchi M; Ohta M; Tsukamoto S
    Bioorg Med Chem; 2009 Oct; 17(19):6926-36. PubMed ID: 19747833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2017 May; 25(10):2813. PubMed ID: 28366269
    [No Abstract]   [Full Text] [Related]  

  • 37. Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
    Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
    Bioorg Med Chem; 2016 Sep; 24(18):4517. PubMed ID: 27544046
    [No Abstract]   [Full Text] [Related]  

  • 38. Corrigendum to "Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response" [Eur J Med Chem. 192 2020 112158].
    Wu WC; Liu YM; Lin MH; Liao YH; Lai MJ; Chuang HY; Hung TY; Chen CH; Liou JP
    Eur J Med Chem; 2020 Jun; 196():112329. PubMed ID: 32311605
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to "Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer" [Eur. J. Med. Chem. 238 (2022) 1-20/114484].
    Cui H; Hu Z; Yang K; Huang J; Wu Y; Chen Q; Wei R; Wang P; Wang H; Li H; Chen Y; Lu T; Yao Y; Zhu Y
    Eur J Med Chem; 2022 Oct; 240():114568. PubMed ID: 35809536
    [No Abstract]   [Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents.
    Liu Z; Wu S; Wang Y; Li R; Wang J; Wang L; Zhao Y; Gong P
    Eur J Med Chem; 2014 Nov; 87():782-93. PubMed ID: 25440879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.